A Phase I Feasibility Study of an Intracortical Visual Prosthesis (ICVP) for People With Blindness

NCT ID: NCT04634383

Last Updated: 2022-01-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-20

Study Completion Date

2023-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the feasibility of producing artificial vision in persons with blindness. Study participants will have wireless electrical stimulators implanted into the cortical vision processing areas of their brains. The ability of the participants to perceive artificial vision in response to electrical stimulation will be assessed.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study is to test the safety of the ICVP system and the feasibility of eliciting visual percepts in response to electrical stimulation in persons with blindness. The electrical stimulation is provided by wireless floating microelectrode arrays (WFMAs) that are part of the ICVP system. The WFMAs are implanted in the visual cortex. Five participants will take part in the study and each participant will have multiple WFMA devices implanted in their visual cortex on one side of the brain. After recovery from surgery, participants will begin a series of tests to assess the ability of electrical stimulation to induce visual percepts and how these percepts may provide some measure of artificial vision. Weekly participant testing will occur over a period of one to three years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ocular Injury Optic Nerve Diseases Photoreceptor Degeneration Blindness,Acquired

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Eligible participants for the study will be persons with blindness who meet the listed inclusion criteria. Individuals having any of the listed exclusion criteria will not be eligible to participate in the study. Enrolled participants will receive electrical stimulation devices implanted in the cortical region of their brain that is involved in vision processing. A maximum of five participants will be implanted. Written Informed Consent will be obtained from all participants before they are enrolled in the study.
Primary Study Purpose

DEVICE_FEASIBILITY

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

WFMA Cortical Visual Prosthesis Single-arm Study

The WFMA is an electronic device that is implanted in the cortical vision processing regions of the brain to produce artificial vision.

Group Type EXPERIMENTAL

WFMA - wireless floating microelectrode array

Intervention Type DEVICE

Wirelessly transmitted patterns of electrical stimulation will be delivered to the visual cortex of study participants to generate visual percepts.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

WFMA - wireless floating microelectrode array

Wirelessly transmitted patterns of electrical stimulation will be delivered to the visual cortex of study participants to generate visual percepts.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ICVP System ICVP Intracortical Visual Prosthesis

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* No light perception or bare light perception, in each eye in accordance with relevant International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes, where the physician has no expectation of improvement through currently approved treatments.
* History of normal or near-normal vision, with or without refractive correction, during at least the first 10 years of life.
* Adjusted to blindness for at least one year.
* History of vision or blindness rehabilitation.
* Willing and able to meet the time demands of the study with transportation assistance.
* Willing to agree to audio and video recording, as specified in the pre-screening consent.
* Motivated by altruism, willingness to participate in pioneering science.
* Demonstrated support from spouse, family and/or friends.
* High or average cognitive and spatial functioning.
* Normal structural MRI.
* English as preferred language.
* Normal decision-making capacity.

Exclusion Criteria

* Poor adjustment to blindness, or vision loss within the last year.
* Expectation of vision restoration to pre-blindness level through trial participation.
* History of alcohol or drug dependence.
* Evidence of prior immune response to an orthopedic implant which caused the implant to be explanted
* A disease prognosis of living less than five years.
* An implant which would prevent screening using MRI, or a pacemaker, or similar implant.
* A history of seizures.
* Current suicidal ideation.
* Poor decision-making capacity.
* Current diagnosis or history of severe mental illness.
* Women who are pregnant or plan on becoming pregnant in the duration of the trial.
* Hand Motion (HM) vision or better vision,
* No Light Perception (NLP) or Light Perception (LP) vision with present OptoKinetic Nystagmus (OKN)
* NLP vision with pupil constriction
* Patients with Islands of perceivable vision in Goldmann Visual Field or Confrontational visual Field will also be excluded from the study.
* Patients with Complete media opacity (complete cornea opacity, very dense cataract) that does not allow visualization of the posterior segment to determine the cause of blindness will be excluded from the study. Only patients with NLP and LP vision without OKN will be included in the study.
* Patients with NLP or LP vision since birth will also be excluded from the study, as they may not have fully developed higher visual pathways, including cortical connections
Minimum Eligible Age

19 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

Sponsor Role collaborator

Rush University Medical Center

OTHER

Sponsor Role collaborator

The Chicago Lighthouse

OTHER

Sponsor Role collaborator

The University of Texas at Dallas

OTHER

Sponsor Role collaborator

University of Chicago

OTHER

Sponsor Role collaborator

Johns Hopkins University

OTHER

Sponsor Role collaborator

Illinois Institute of Technology

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Philip R Troyk, PhD

Role: PRINCIPAL_INVESTIGATOR

Illinois Institute of Technology

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Illinois Institue of Technology

Chicago, Illinois, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Recruitment Director

Role: CONTACT

312-567-5304

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Principal Investigator

Role: primary

312-567-5304

References

Explore related publications, articles, or registry entries linked to this study.

Bak M, Girvin JP, Hambrecht FT, Kufta CV, Loeb GE, Schmidt EM. Visual sensations produced by intracortical microstimulation of the human occipital cortex. Med Biol Eng Comput. 1990 May;28(3):257-9. doi: 10.1007/BF02442682. No abstract available.

Reference Type BACKGROUND
PMID: 2377008 (View on PubMed)

Schmidt EM, Bak MJ, Hambrecht FT, Kufta CV, O'Rourke DK, Vallabhanath P. Feasibility of a visual prosthesis for the blind based on intracortical microstimulation of the visual cortex. Brain. 1996 Apr;119 ( Pt 2):507-22. doi: 10.1093/brain/119.2.507.

Reference Type BACKGROUND
PMID: 8800945 (View on PubMed)

Stephan K, Troyk PR, Dagnelie G, Cogan S, Barry MP, Grant P, Lane F, Szlyk JP, McNulty M, van Drongelen W, Pham TH, Stipp KL, Royster M, Towle VL. The Role of Scalp EEG Recordings During Cortical Visual Prosthesis Testing. Artif Organs. 2025 May 27:10.1111/aor.15023. doi: 10.1111/aor.15023. Online ahead of print.

Reference Type DERIVED
PMID: 40421717 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

UH3NS095557

Identifier Type: NIH

Identifier Source: secondary_id

View Link

ICVP0001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Corneal Sensitivity Cross-linking Keratoconus
NCT01743443 COMPLETED PHASE2/PHASE3